All In Biotech

Drug Trial Radar · NCT04834869

COVID-19 Vaccines Safety Tracking (CoVaST)

COVID-19 Vaccines Safety Tracking: Global Consortium Study

Last checked: Nov 20, 2026Latest source record: Apr 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30,000

Planned (sponsor's estimate)

Start

Apr 1, 2021

Primary completion

Dec 31, 2025

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Masaryk UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 8, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This project aims to monitor the side effects of COVID-19 vaccines worldwide actively. The primary objectives of the project include a) to estimate the prevalence of each local and systemic side effect of each COVID-19 vaccine among healthcare workers (HCW), old adults over +65 (OA), and schoolteachers (ST); b) to evaluate the potential demographic and medical risk factors for side effects frequency and intensity; c) to evaluate the long-term consequences of COVID-19 vaccines. The secondary objectives include a) to evaluate the relative safety of COVID-19 vaccines compared to each other; b) to evaluate the impact of palliative drugs used by the recently vaccinated individuals on their short-term side effects resolution.

Conditions

  • Adverse Reaction to Vaccine
  • COVID19 Vaccine

Interventions

  • BNT162b2Biological

    Receiving either the first dose only or both doses of BNT162b2 vaccine (Pfizer-BioNTech COVID-19 Vaccine)

  • mRNA-1273Biological

    Receiving either the first dose only or both doses of mRNA-1273 vaccine (Moderna COVID-19 Vaccine)

  • AZD1222Biological

    Receiving either the first dose only or both doses of AZD1222 vaccine (AstraZeneca-Oxford University COVID-19 Vaccine)

  • CoronaVacBiological

    Receiving either the first dose only or both doses of CoronaVac (Sinovac COVID-19 Vaccine)

  • SinopharmBiological

    Receiving either the first dose only or both doses of Sinopharm Vero Cell COVID-19 Vaccine

  • Gam-COVID-VacBiological

    Receiving either the first dose only or both doses of Gam-COVID-Vac (Sputnik V)

  • JNJ-78436735Biological

    Receiving JNJ-78436735 (Janssen COVID-19 Vaccine)

  • CVnCoVBiological

    Receiving either the first dose only or both doses of CVnCoV (CureVac COVID-19 vaccine)

  • NVX-CoV2373Biological

    Receiving either the first dose only or both doses of NVX-CoV2373 (Novavax COVID-19 vaccine)

  • BBV152Biological

    Receiving either the first dose only or both doses of BBV152 (Covaxin COVID-19 vaccine)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Local Side EffectsTime frame: 0-30 days after the COVID-19 vaccine shot
  2. Systemic Side EffectsTime frame: 0-30 days after the COVID-19 vaccine shot

Locations

14 sites in 14 countries. Site status is shown where the registry gives one.

  • American College of Physicians

    Philadelphia, Pennsylvania · Not yet recruiting

  • McMaster University

    Hamilton, Ontario, Canada · Not yet recruiting

  • University of Split

    Split, Croatia · Not yet recruiting

  • Masaryk University

    Brno, Czechia · Recruiting

  • University of Tartu

    Tartu, Estonia · Not yet recruiting

  • Jimma University

    Jimma, Ethiopia · Recruiting

  • Justus-Liebig University Giessen

    Giessen, Germany · Recruiting

  • University of Ghana

    Accra, Ghana · Not yet recruiting

  • Sinaloa's Pediatric Hospital

    Culiacán, Mexico · Not yet recruiting

  • Medical University of Silesia

    Katowice, Poland · Recruiting

  • Nursing School of Coimbra

    Coimbra, Portugal · Not yet recruiting

  • Irkutsk Scientific Center of Siberian Branch of Russian Academy of Sciences

    Irkutsk, Russia · Recruiting

  • University of Belgrade

    Belgrade, Serbia · Recruiting

  • University of Ljubljana

    Ljubljana, Slovenia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.